Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2009 Feb;32(1):15-9.
doi: 10.1097/COC.0b013e318178e513.

Phase I trial of weekly topotecan and gemcitabine in patients with solid tumors

William N William Jr  1 , Joseph L Lee, Dong M Shin, Waun K Hong, Suyu Liu, J Jack Lee, Scott M Lippman, Fadlo R Khuri, Edward S Kim
Affiliations
Clinical Trial

Phase I trial of weekly topotecan and gemcitabine in patients with solid tumors

William N William Jr et al. Am J Clin Oncol. 2009 Feb.

Abstract

Objective: This phase I trial was designed to determine the maximal tolerated dose (MTD) of the combination of topotecan and gemcitabine given in a weekly schedule.

Materials and methods: In this single-arm, open label, dose-escalation study, we administered topotecan (0.75-1.5 mg/m) and gemcitabine (1000 mg/m) on days 1, 8, and 15 every 4 weeks to 25 patients with advanced solid tumors.

Results: The topotecan MTD, when combined with gemcitabine, was 1.25 mg/m/wk. Dose-limiting toxicities consisted of febrile granulocytopenia in 2 patients at the highest dose level. At the MTD, no episodes of granulocytopenia were observed, whereas 2/9 patients exhibited grade 3 thrombocytopenia. Other common grades 3-4 adverse events across all cohorts included non-neutropenic infections, fatigue, skin reactions, vomiting, and fever. One partial response and 2 stable diseases were observed in patients with nasopharyngeal carcinoma. Disease stabilization was also observed in patients with squamous cell carcinoma of the head and neck (3), nonsmall cell lung cancer (1), and thymoma (1).

Conclusions: Topotecan and gemcitabine combined in a weekly schedule exhibit a favorable toxicity profile. Efficacy results support the further evaluation of this regimen in patients with head and neck cancer (particularly nasopharyngeal carcinoma).

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Kollmannsberger C, Mross K, Jakob A, et al. Topotecan—a novel topoisomerase I inhibitor: pharmacology and clinical experience. Oncology. 1999;56:1–12. - PubMed
    1. ten Bokkel Huinink W, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol. 1997;15:2183–2193. - PubMed
    1. von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol. 1999;17:658–667. - PubMed
    1. Long HJ, III, Bundy BN, Grendys EC, Jr, et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol. 2005;23:4626–4633. - PubMed
    1. Eckardt JR. Emerging role of weekly topotecan in recurrent small cell lung cancer. Oncologist. 2004;9(suppl 6):25–32. - PubMed

Publication types